Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (15130)	1/6/2005 4:59:41 PM
From: Rudy Saucillo	Respond to of 52153

The question of "how" anti-inflammatory agents like AGI-1067 regress plaque has been raised both on this board and the Yahoo AGIX board. There appears to be a link between reducing myelopereoxidase (the inflammation marker that 1067 impacts) and plaque regression. This abstract describes the myelopereoxidase pathway resulting in oxidized HDL. The abstract also describes how cholesterol transport (reverse lipid transport) function is impaired by this oxidized HDL. "The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport." ncbi.nlm.nih.gov So this is the implied mechanism...1067 reduces levels of myeloperoxidase resulting in lower levels of oxidized HDL. Lower levels of oxidized HDL implies improved cholesterol transport function (ability to remove cholesterol from artery walls) facilitating plaque regression.